Forest Laboratories Announces Federal Appeals Court Upholds Lexapro(R) Patent Decision
September 05 2007 - 12:24PM
PR Newswire (US)
NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Forest Laboratories,
Inc. (NYSE:FRX) and H. Lundbeck A/S of Denmark said today that the
U.S. Court of Appeals for the Federal Circuit has affirmed a July
13, 2006 decision by the U.S. District Court for the District of
Delaware which determined that the U.S. patent covering
escitalopram, the active ingredient in Lexapro(R), is valid and
upheld the injunction preventing Ivax/Teva's proposed generic
product launch, thereby confirming Forest's and Lundbeck's patent
rights for Lexapro(R), which expire in March 2012. (Logo:
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO ) The
patent at issue in the U.S. lawsuit is Lexapro's patent (U.S.
Patent No. Re 34,712), which is set to expire in March 2012 and
covers substantially pure escitalopram. About Forest Laboratories
and Its Products Forest Laboratories (http://www.frx.com/) is a
US-based pharmaceutical company dedicated to identifying,
developing and delivering products that make a positive difference
in peoples' lives. Forest Laboratories' growing product line
includes Lexapro(R) (escitalopram oxalate), an SSRI indicated for
adults for the initial and maintenance treatment of major
depressive disorder and generalized anxiety disorder; Namenda(R)
(memantine HCl), an N-methyl D- aspartate (NMDA)-receptor
antagonist indicated for the treatment of moderate to severe
Alzheimer's disease; Benicar(R)* (olmesartan medoxomil), an
angiotensin receptor blocker, and Benicar* HCT(R) (olmesartan
medoxomil- hydrochlorothiazide), an angiotensin receptor blocker
and diuretic combination product, each indicated for the treatment
of hypertension; and Campral(R)* (acamprosate calcium), indicated
in combination with psychosocial support for the maintenance of
abstinence from alcohol in patients with alcohol dependence who are
abstinent at treatment initiation. *Benicar is a registered
trademark of Daiichi Sankyo, Inc., and Campral is a registered
trademark of Merck Sante s.a.s., subsidiary of Merck KGaA,
Darmstadt, Germany. Except for the historical information contained
herein, this release contains "forward-looking statements" within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements involve a number of risks and uncertainties,
including the difficulty of predicting FDA approvals, the
acceptance and demand for new pharmaceutical products, the impact
of competitive products and pricing, the timely development and
launch of new products, and the risk factors listed from time to
time in the Forest Laboratories' SEC reports, including the
Company's Annual Report on Form 10-K for the fiscal year ended
March 31, 2007 and quarterly report on form 10-Q for the period
ended June 30, 2007.
http://www.newscom.com/cgi-bin/prnh/20001011/FORESTLOGO
http://photoarchive.ap.org/ DATASOURCE: Forest Laboratories, Inc.
CONTACT: Charles E. Triano, Vice President-Investor Relations of
Forest Laboratories, Inc., +1-212-224-6714, Web site:
http://www.frx.com/
Copyright
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From May 2024 to Jun 2024
Forest Road Acquisition (NYSE:FRX)
Historical Stock Chart
From Jun 2023 to Jun 2024